Baird analyst Joel Beatty raised the firm’s price target on Axsome Therapeutics (AXSM) to $162 from $160 and keeps an Outperform rating on the shares. The firm updated its model following strong Q1 results and where the Symbravo launch is on track for June.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $165 from $160 at Wells Fargo
- Axsome Therapeutics: Strong Market Performance and Promising Growth Potential with Key Catalysts Ahead
- Axsome Therapeutics: Strong Growth Potential with Auvelity’s Market Expansion and Strategic Initiatives
- Axsome Therapeutics Reports Strong Q1 2025 Growth
- Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges